课题基金 / 基金详情

Modulation of Therapeutic Response

Modulation of Therapeutic Response
治疗反应的调节
批准号:
8158259
负责人:
James Mitchell
金额:
$64.92万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:

项目摘要

项目成果

James Mitchell的其他基金

相似基金

相关文献

中文摘要
翻译
为了提高癌症的治疗水平,辐射损伤的修饰受到了极大的关注。各种化疗和/或分子靶向药物与辐射的相互作用正在研究中,以确定是否可以使肿瘤更敏感,或使正常组织对放射治疗更具抵抗力。中心目标是确定将导致净治疗收益的方法,从而改善癌症的放射治疗。该项目的目标之一是定义和更好地了解肿瘤生理学的这些方面,包括细胞和分子过程以及肿瘤微环境对治疗反应的影响。增强肿瘤对辐射的反应,而不增强给定治疗范围内的正常组织的能力是可取的。我们最近发现氯雷他定、常青藤酮和苦参酮在体外可以增强肿瘤细胞的放射反应。这些药物通过不同的机制提高放射敏感性,包括细胞周期重新分配、抑制辐射诱导的修复和抑制转化生长因子-β信号转导。一种分子靶向的Chk-1抑制剂在p53突变的人类肿瘤细胞系中显示出显著的放射敏感性。正常人成纤维细胞(野生型P53)不受该药的辐射增敏,提示肿瘤增敏作用不同。该试剂在体内也提供了相当大的辐射增强,几乎没有正常的组织毒性。虽然这种药物消除了正常辐射诱导的G2期细胞周期的延迟,但抑制辐射损伤的修复似乎是辐射增敏的主要机制。与放射肿瘤科合作,正在提交一项临床试验,以评估该制剂对结直肠癌的治疗。我们还在评估一种CK2抑制剂,初步数据显示,该试剂是一种有效的体外放射增敏剂,可用于人类肿瘤细胞系。初步研究正在评估一种IGF-1R抗体,一种抗血管生成剂,以及一种作为辐射修饰剂的外周蛋白类似物。关于正常组织对辐射的反应,众所周知,转化生长因子-β信号通路是辐射诱导的晚期效应(纤维化)的主要参与者。我们以前的研究表明,缺乏转化生长因子-β信号的小鼠(Smad3基因敲除小鼠--转化生长因子-β途径的下游信号中间体)在接受高剂量辐射治疗时对纤维化具有抵抗力。最近使用一种转化生长因子-β1型受体激酶抑制剂的小鼠正常组织研究表明,辐射诱导的软组织纤维化显著减少。该药物可阻断转化生长因子-β信号通路。最后,我们有初步的临床前数据表明,氮氧化物,坦普尔(全身和局部应用)可以预防放射性口腔粘膜炎。口腔粘膜炎是头颈部癌症放射治疗中常见的毒性反应。我们还在初步研究中表明,Tempoll不会改变与肿瘤再生延迟相关的化疗和放射治疗,为将这些实验药物引入人类放射肿瘤学临床试验提供了更多数据。
英文摘要
In the interest of improving cancer treatment, considerable attention has been placed on the modification of radiation damage. The interaction of a variety of chemotherapy and/or molecularly targeted agents with radiation is under study to determine if tumors can be made more sensitive or normal tissues more resistant to radiation treatment. The central aim is to identify approaches that will result in a net therapeutic gain, thus improving cancer treatment with radiation. One goal of the project is to define and better understand those aspects of tumor physiology, including cellular and molecular processes and the influence of the tumor microenvironment on treatment response. The ability to enhance the response of the tumor to radiation, without enhancing normal tissue within a given treatment field is desirable. We have recently shown that loratadine, halofuginone, and guggulsterone enhance tumor cell radiation response in vitro. These agents enhance radiosensitivity by different mechanisms including cell cycle redistribution, inhibition of radiation-induced repair, and inhibition of TGF-beta signaling. A molecularly targeted Chk-1 inhibitor has demonstrated significant radiosensitive in p53 mutated human tumor cell lines. Normal human fibroblasts (p53 wild type) are not radiosensitized by this agent suggesting differential tumor sensitization. This agent also provides considerable radiation enhancement in vivo with very little to no normal tissue toxicity. While this agent abrogates the normal radiation-induced delay in G2 of the cell cycle, inhibition of repair of radiation damage appears to be the major mechanism of radiosensitization. In collaboration with the Radiation Oncology Branch a clinical trial is being submitted to evaluate this agent in colorectal cancer. We are also evaluating a CK2 inhibitor and preliminary data show this agent to be an effective in vitro radiation sensitizer of human tumor cell lines. Preliminary studies are underway evaluating an IGF-1R antibody, an anti-angiogenesis agent, and an epilone analogue as radiation modifiers. With respect to normal tissue response to radiation, it is widely known that the TGF-beta signaling pathway is a major player in radiation-induced late effects (fibrosis). Our previous studies have shown that mice deficient in TGF-beta signaling (Smad3 knock-out mice-downstream signaling intermediate in the TGF-beta pathway) are resistant to fibrosis when treated with high dose radiation. Recent mouse normal tissue studies using a TGF-beta type 1 receptor kinase inhibitor have shown marked reduction in radiation-induced soft tissue fibrosis. This agent blocks the TGF-beta signaling pathway. Lastly we have preliminary pre-clinical data suggesting that the nitroxide, Tempol (both systemic and topically applied) protects against radiation-induced oral mucositis. Oral mucositis is a common toxicity associated with the radiation treatment of head and neck cancers. We have also shown in preliminary studies that Tempol does not alter chemoradiation with respect to tumor regrowth delay, providing more data to introduce these experimental agents into human radiation oncology clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nitroxides as Protectors Against Oxidative Stress
Modulation of Therapeutic Response
Modulation of Therapeutic Response
Protection against Radiation-Induced Carcinogenesis
  • 批准号:
    8349242
  • 项目类别:
  • 资助金额:
    $32.13万
  • 财政年份:
    --
  • 负责人:
    James Mitchell
  • 依托单位:
国内基金
海外基金
RIPK3蛋白及其RHIM结构域在脓毒症早期炎症反应和脏器损伤中的作用和机制研究
  • 批准号:
    82372167
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    江继宏
  • 依托单位:
YTHDF1通过m6A修饰调控耳蜗毛细胞炎症反应在老年性聋中的作用机制研究
  • 批准号:
    82371140
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    李姝娜
  • 依托单位:
基于FCER1G基因介导免疫反应探讨迟发性聋与认知障碍相关性的机制研究
  • 批准号:
    82371141
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    陈颖
  • 依托单位:
cGAS-STING激活IFN1反应介导噪声性耳蜗损伤机制研究
  • 批准号:
    82371152
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    冯艳梅
  • 依托单位: